Search Medical Condition
Please enter condition
Please choose location

Glendale, California Clinical Trials

A listing of Glendale, California clinical trials actively recruiting patient volunteers.

RESULTS

Found (876) clinical trials

Phase 1 TAK-041 First-in-Human Safety Tolerability and Pharmacokinetics Study

The drug being tested in this study is called TAK-041. TAK-041 is being tested to evaluate the safety, tolerability, and pharmacokinetics (PK) of single and multiple doses of TAK-041 in healthy participants. The study will enroll approximately 40 participants. The study is composed of 2 parts. Part 1 (single-rising dose ...

Phase

0.0 miles

Learn More »

Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants

TAK-071 is being tested to find a safe and well-tolerated dose in healthy participants (non-Japanese and Japanese) and participants with MCI or mild AD (non-Japanese). The study will enroll approximately 186 participants. The study consists of 4 parts: Single-rising dose (SRD) part (Cohorts 1-6, and 18-22), multiple-rising dose (MRD) part ...

Phase

0.0 miles

Learn More »

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Subjects With Dialysis-dependent Chronic Kidney Disease (DD-CKD)

This is a multicenter, randomized, open-label, active-controlled Phase 3 study of the efficacy and safety of vadadustat versus darbepoetin alfa for the maintenance treatment of anemia in subjects with DD-CKD

Phase

0.0 miles

Learn More »

Does Lung Impedance Correlate With Changes in BNP in Stable and Acutely Decompensated Heart Failure Patients?

This is a prospective non-randomized longitudinal study. One hundred subjects will participate in 6 monthly and 3 bi-monthly serial assessments of plasma-based BNP, implantable device measured intrathoracic impedance, and clinical evaluation of heart failure status. Each patient will be enrolled in the study for a period of 12 months.

Phase N/A

0.0 miles

Learn More »

TAK-071 Scopolamine-Induced Cognitive Impairment Study

The drug being tested in this study is called TAK-071. This study will look at the effect of a single oral dose of TAK-071, a novel muscarinic acetylcholine receptor 1 positive allosteric modulator, on scopolamine-induced deficits in cognitive function in healthy adult male participants. The study consists of two parts: ...

Phase

0.0 miles

Learn More »